Thiogenesis Therapeutics Corp's next confirmed earnings release is scheduled for November 24, 2026.
| Earnings Date | 11/24/2026 |
As of June 30, 2026, Thiogenesis Therapeutics Corp has 69.98M shares outstanding.
| Shares Outstanding | 69.98M |
As of June 30, 2026, Thiogenesis Therapeutics Corp maintains a current ratio of 10.81, meaning it holds 10.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.81 |
| Quick Ratio | 10.69 |
Over the twelve months ended June 30, 2026, Thiogenesis Therapeutics Corp posted a negative return on equity (ROE) of -181.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -139.41, reflecting losses generated across the asset base.
| Return on Equity (ROE) | -181.53 |
| Return on Assets (ROA) | -139.41 |
As of the close on October 30, 2026, Thiogenesis Therapeutics Corp's stock has gained approximately 14.81% over the past 52 weeks.
| 52-Week Price Change | 14.81% |
Over the twelve months ended June 30, 2026, Thiogenesis Therapeutics Corp generated - - in revenue and converted that into -6.52M in net income, yielding earnings per share of -0.12. EBITDA reached -6.52M, while operating income came in at -6.52M.
| Operating Income | -6.52M |
| Pretax Income | -6.52M |
| Net Income | -6.52M |
| EBITDA | -6.52M |
| EBIT | -6.52M |
| Earnings Per Share (EPS) | -0.12 |
These figures are as of June 30, 2026. Total book value stands at 6.72M, with working capital of 6.72M providing operational flexibility.
| Cash & Cash Equivalents | 7.27M |
| Net Debt | -7.27M |
| Equity (Book Value) | 6.72M |
| Book Value Per Share | 0.10 |
| Working Capital | 6.72M |
Thiogenesis Therapeutics Corp produced -6.73M in operating cash flow over the twelve months ended June 30, 2026.
| Operating Cash Flow | -6.73M |
| Free Cash Flow | -6.73M |
| FCF Per Share | -0.13 |
Already premium?